Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allonix LRH-1 agonist
- Development stage
- Preclinical
- Lead developer
- Allonix Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Allonix Therapeutics is developing a first-in-class oral small molecule agonist of liver receptor homologue-1 (LRH-1), a nuclear hormone receptor also known as nuclear receptor subfamily 5 group A member 2 (NR5A2). LRH-1 plays a critical role in regulating inflammation, cholesterol homeostasis, and cellular metabolism. The drug is designed to bind to LRH-1 in intestinal cells to stimulate the local production of corticosteroids, thereby reducing inflammation and promoting the healing and regeneration of damaged gut tissue. This localized approach is intended to treat inflammatory bowel disease (IBD), specifically ulcerative colitis, while minimizing the systemic side effects associated with traditional corticosteroid therapies. The program is currently in the preclinical stage and has received support from the Crohn's & Colitis Foundation's IBD Ventures program.
- Other names
- LRH-1 agonistLRH1 agonistLRH 1 agonist
02
Targets
NR5A2 (Purinergic receptor P2X5)
Beyond the preview
Go deeper on Allonix LRH-1 agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allonix LRH-1 agonist.